Active Ingredient(s):Entrectinib FDA Approved: * August 15, 2019 Pharm Company: *GENENTECH INC Category:Cancer
Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).
The most common side effects include tiredness, constipation, dysgeusia (taste disturbances), edema (swelling with flui...
* May have multiple approval dates, manufacturers, or labelers.